These findings complement the work of a major research project underway: the
Canadian Prostate Cancer Genome Network (CPC-GENE). The aforementioned study focuses on identifying those most at risk for prostate cancer to better direct screening efforts; it does not perfectly predict which patients have indolent disease and which patients have aggressive disease.
The goal of CPC-GENE is to “crack” that prostate cancer genetic code to be able to predict personalized treatments for non-indolent and localized intermediate risk prostate cancers – a slightly more specific goal and target population. In time, this could mean that doctors could offer additional treatment options to patients whose cancer possesses genetic components that predict success or failure of a specific treatment. The CPC-GENE and associated clinicians will then escalate therapy to a specific group of patients to reduce the risk of treatment failure and improve overall rates of cure.